about
Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer.Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.Does PET SUV Harmonization Affect PERCIST Response Classification?NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System.Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4-2008 image quality parametersThe importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria.Patient's weight: a neglected cause of variability in SUV measurements? A survey from an EARL accredited PET centre in 513 patients.Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.Correction to: Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.Diuretic ¹⁸F-FDG PET/CT for therapy monitoring in urothelial bladder cancer.Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomicsBaseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy
P50
Q36254165-0E11501B-EAE7-4978-8577-69BF1A9B8835Q36920672-7BA8DD4D-A500-4777-86EC-64E4A000B858Q38035192-26DB4C33-22AC-4C99-9726-30CC678749C8Q39216200-DCA44068-1A21-419B-AE13-1F2EE23DFE04Q39694600-73B9126F-9F19-432D-96EA-BE99A59DFD3AQ41737043-4B27B509-A771-422A-B2FD-AFF8D31710C1Q41781081-B406FB17-CE34-480D-9EF1-CA58687681E7Q42609671-E3147BEF-9B10-49D3-8F53-BE1D2BDE992CQ47353613-C09B8057-16CE-4D3B-87E5-64C33B10C49DQ48163208-19F2D8CB-CC6B-44DB-9EF0-04ED090D1051Q48248991-D42176BF-05D5-41D7-9C92-413277132ED3Q48329992-C315D37F-B6F4-42CA-A50D-8C84D1C16C29Q53063928-1E7B97E2-F48A-4850-8537-ED54770FAF52Q60926140-AD42D755-D29C-4876-A5AF-A9424A3015D3Q91572549-07EE9105-38C2-441A-9110-F20704E0011F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Charline Lasnon
@ast
Charline Lasnon
@en
Charline Lasnon
@es
Charline Lasnon
@nl
Charline Lasnon
@sl
type
label
Charline Lasnon
@ast
Charline Lasnon
@en
Charline Lasnon
@es
Charline Lasnon
@nl
Charline Lasnon
@sl
prefLabel
Charline Lasnon
@ast
Charline Lasnon
@en
Charline Lasnon
@es
Charline Lasnon
@nl
Charline Lasnon
@sl
P214
P106
P214
P31
P496
0000-0001-5643-1668
P7859
viaf-296028353